| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry |
Wellcome/CRC Institute, Cambridge, CB2 1QR; and Department of Zoology, University of Cambridge, Cambridge, CB2 3EJ, United Kingdom
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
470,000) catalytic subunit, DNA-PKcs, and a DNA targeting component, termed Ku (4, 5, 6)
. Ku, first identified as a human autoimmune antigen, is a heterodimer composed of polypeptides of Mr 70,000 and 80,000 (Ku70 and Ku80, respectively). Both components of DNA-PK function in the repair of DNA damage induced by IR and, hence, show a reliance on each other for generating a functional holoenzyme in vivo (7, 8, 9)
. Cells defective in Ku components (such as xrs-6 and lines derived from Ku70-/- and Ku80-/- mice) are not only sensitive to DNA double-strand break-inducing agents but are also defective in the site-specific nonhomologous end-joining process of V(D)J recombination (7, 8, 9)
. The severe combined immunodeficient mouse possesses a truncated DNA-PKcs polypeptide that appears to lack kinase activity, and this also results in defective V(D)J recombination and an inability to effectively repair IR-induced DNA double-strand breaks (10, 11, 12)
. It has been shown recently that DNA-PKcs can bind to and be activated by DNA in a Ku-independent manner in vitro (13
, 14)
. However, because Ku-deficient cells show similar phenotypes to DNA-PKcs-deficient cells, it is likely that Ku is required for DNA-PK function in physiological situations.
Cloning of the DNA-PKcs cDNA revealed that its open reading frame directs the synthesis of a protein of 4100 amino acid residues (6)
. Other than a leucine zipper motif found between residues 1503 and 1538, which appears to be involved in interacting with the nuclear matrix protein C1D (15)
, the only clearly identifiable functional motif in the DNA-PKcs polypeptide is the kinase domain comprising the 400 COOH-terminal amino acid residues. This region shows very little homology to classical serine/threonine kinases, but it shows much greater sequence similarity with the catalytic domains of proteins involved in the phosphorylation of PI, notably PI 3-kinases and PI 4-kinases (16)
. Other polypeptides shown to contain this PI 3-kinase-like domain include several proteins implicated in DNA repair, genome surveillance, and cell cycle checkpoint controls: mammalian ATM, ATR, and FRAP, together with homologues of these in systems such as Saccharomyces cerevisiae and Schizosaccharomyces pombe (17)
. To date, members of this latter group have not been shown unequivocally to possess an intrinsic ability to phosphorylate phosphatidlyinositols and are, therefore, most probably protein serine/threonine kinases (18)
.
Wortmannin is a seterol-like fungal metabolite that has been shown previously to be a potent and selective inhibitor of mammalian PI 3-kinase (19
, 20)
. On the basis of the similarity between the kinase domains of DNA-PKcs and PI 3-kinases, we and others have established that wortmannin is able to inhibit DNA-PK function in vitro (6
, 21, 22, 23)
. However, the IC50 (concentration at which 50% of activity is lost) for wortmannin toward DNA-PK is, at 250 nM, 2 orders of magnitude higher than that for PI 3-kinase. Nevertheless, this observation has led to the demonstration by other groups that cells grown in the presence of wortmannin are sensitized to the killing effects of IR (24, 25, 26, 27)
. Therefore, in this context, wortmannin acts as a radiosensitizing agent. Although the above effects suggest that the radiosensitization is via DNA-PK inhibition, the possibility exists that wortmannin also impairs the function of other members of the PI 3-kinase family, such as ATM or ATR (17
, 18
, 23
, 28)
. More recently, it has been shown that another PI 3-kinase inhibitor, LY294002, is also able to sensitize cells to the effects of IR (26)
.
Because of the potential use of wortmannin, LY294002, and their derivatives as radiosensitizers, we have sought to provide a detailed analysis of their inhibition of DNA-PK. Here, we provide a kinetic analysis of the PI 3-kinase inhibitors wortmannin, quercetin, quercitrin, rutin, and LY294002 toward DNA-PK. Furthermore, we have used wortmannin as a probe for DNA-PK function in vitro. Our data not only provide a detailed analysis of DNA-PK inhibitors in vitro but also serve to broaden the known effects of wortmannin and quercetin derivatives. We are also able to show here that wortmannin can bind directly to DNA-PKcs in vivo. Our data provide a starting point for the development of more specific inhibitors of PI 3-kinase family members and potentially novel radiosensitizers.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Chemicals.
Wortmannin, quercetin, and LY294002 were obtained from Alexis Corporation (UK) Ltd. (Nottingham, United Kingdom). Rutin and quercitrin were purchased from Sigma (Poole, United Kingdom).
Inhibitor Studies.
DNA-PK assays were performed as described previously using a p53-based peptide substrate (30
, 31)
. For inhibition experiments, wortmannin was added to the reaction mixture at the same time as ATP. For the other inhibitors, these were preincubated with DNA-PK for 5 min prior to ATP addition. All chemical inhibitors were dissolved in 10% DMSO, resulting in a final DMSO concentration of 1% in the assay mixture. DMSO (1%) was found not to adversely affect the DNA-PK assay.
DNA-PK/DNA-PKcs.
DNA-PK holoenzyme and DNA-PKcs were purified from HeLa nuclear extract (Computer Cell Culture Centre, Mons, Belgium) essentially as described previously (32)
.
Wortmannin Labeling of DNA-PK.
Nuclear extract (10 µg), purified DNA-PK (600 ng), or DNA-PKcs (100 ng) was labeled with wortmannin (10 µM) at room temperature for 20 min in buffer containing 5 mM HEPES (pH 7.6), 40 mM KCl, 4% glycerol, 0.2 mM MgCl2, and 1 mM DTT. Wortmannin-labeled proteins were identified by standard SDS-PAGE (7% polyacrylamide gels) and Western blotting analysis with the use of antiwortmannin antiserum kindly provided by M. Wymann (Fribourg, Switzerland; Ref. 33). In vivo labeling of cells was carried out by adding wortmannin to a final concentration of 10 or 100 µM to the growth medium for 90 min. Nuclear extract was prepared from harvested cells by the method of Dignam et al. (34)
. Wortmannin-labeled proteins were identified as outlined above. For limited proteolysis of DNA-PKcs, 1 or 3.3 µl of recombinant caspase-3 (Pharmingen, San Diego, CA) was added to 600 ng of DNA-PK labeled with 10 µM wortmannin (as above) and incubated at 37°C for 30 min prior to Western blot analysis using anti-DNA-PKcs antiserum (AbFLA; Ref. 35) or antiwortmannin antiserum (33)
.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
250 nM. However, this study did not ascertain the mode of inhibition by wortmannin or provide an accurate Ki. Thus, we assayed DNA-PK activity at a variety of different ATP concentrations in the presence of increasing concentrations of wortmannin. A Lineweaver-Burk plot of this analysis revealed that wortmannin behaves as a noncompetitive inhibitor for the ATP binding site of DNA-PK (Fig. 1A)
. From a Dixon plot of this analysis (reciprocal of the velocity of the reaction plotted against wortmannin concentration), a Ki of 120 nM was obtained (Fig. 1B)
. Because the primary plot of these data could not fully discriminate whether the nature of wortmannin inhibition was noncompetitive or mixed noncompetitive/uncompetitive inhibition, Eadie-Scatchard analysis of the initial data set was performed (Fig. 1C
; Ref. 36
). By plotting the velocity of reaction against velocity over substrate concentration, we show, from the slope of the graphs that are constructed, that the mode of wortmannin inhibition is essentially noncompetitive in nature (36)
.
|
. By plotting the slopes from the primary graph (Fig. 2A)
against the concentration of inhibitor, we calculated a Ki of 6.0 µM (Fig. 2B)
. The competitive nature of LY294002 against ATP for DNA-PK is, thus, in keeping with its mechanism of inhibition for PI 3-kinase (37)
.
|
) revealed that rutin has a Ki of 26 µM, quercetin has a Ki of 110 µM, and quercitrin has a Ki of 208 µM for DNA-PK.
|
100-fold above its IC50 (33)
, we used a range of wortmannin concentrations of up to 10 µM in our initial studies. Notably, and as shown in Fig. 3A
, over a wide range of concentrations, wortmannin does, indeed, form covalent adducts with DNA-PKcs that can be detected by Western blot analysis using the antiwortmannin antibody. Furthermore, as indications of the specificity of this reaction, the two Ku subunits are not targeted by wortmannin, and the formation of wortmannin adducts to DNA-PKcs is competitively inhibited by ATP (Fig. 3B)
.
|
240; Fig. 3C
) and COOH-terminal kinase domain portions of Mr 120,000 and 150,000 (120 and 150; Fig. 3C
). As an approach to help define the site of wortmannin adduct formation on DNA-PKcs, we, therefore, used recombinant caspase-3 to perform limited proteolysis on DNA-PKcs that had been pretreated with wortmannin. As revealed by probing with AbFLA, a polyclonal antiserum raised against the whole DNA-PKcs polypeptide, caspase-3 treatment cleaves DNA-PKcs into the fragments described previously (Fig. 3C
, left). More significantly, probing the same material with the antiwortmannin rabbit polyclonal antiserum reveals that only the COOH-terminal regions of DNA-PKcs that contain the kinase domain are labeled by wortmannin. We, therefore, conclude that wortmannin forms covalent adducts specifically to the kinase region of DNA-PKcs but not significantly to any other region of the protein.
Binding of Wortmannin to DNA-PKcs Is Not Affected by the Absence of Ku or by the Presence of DNA or a Peptide Substrate.
Next, we used wortmannin and the specific antiserum to this compound to address a variety of questions regarding the status of the DNA-PKcs active site under various circumstances. Previous work has established that DNA-PKcs has an inherent capacity to bind to DNA termini and is activated by the simultaneous presence of the non-sequence-specific DNA-binding protein Ku and DNA ends. To address whether Ku activates DNA-PKcs via opening of the ATP-binding site of the kinase, we added wortmannin to a DNA-PKcs preparation that was essentially devoid of Ku. Importantly, this preparation of DNA-PKcs was inactive in our assays and was found to contain contaminating Ku at a molar ratio of less than 1 part Ku per 100 parts DNA-PKcs. Notably, although devoid of kinase activity toward a peptide substrate, the preparation of DNA-PKcs lacking Ku still effectively forms adducts with wortmannin that can be competed with ATP (Fig. 4A)
. Furthermore, upon addition of purified Ku, no increase in wortmannin binding to DNA-PKcs was observed (Fig. 4B)
. These results, therefore, indicate that the ATP binding site of DNA-PKcs is accessible, irrespective of the presence of Ku, and therefore, Ku is likely to control DNA-PKcs activity in some other manner, such as modulating its ability to mediate ATP hydrolysis or by controlling access to the protein substrate.
|
. Furthermore, we were also unable to see a competitive effect on wortmannin interacting with DNA-PKcs by adding increasing amounts of a DNA-PK peptide substrate (Fig. 4D)
. This suggests that, at least for this peptide, substrate interaction with the DNA-PKcs kinase domain does not modulate binding of wortmannin to key residues in the ATP binding site and suggests that peptide binding occurs to a region distinct from that targeted by wortmannin. On the basis of these results, previous studies on wortmannin interactions with PI 3-kinase, and the sequence homology between DNA-PKcs and the p110 component of PI 3-kinase, the lysine at amino acid residue 3751 of DNA-PKcs is likely to be the site of nucleophilic attack by the furan group of wortmannin.
Binding of Wortmannin to DNA-PKcs in Vivo.
Recent data have shown that treatment of cells with wortmannin can cause marked sensitization to IR (24, 25, 26, 27)
. However, it remains unclear as to whether this radiosensitization is mediated through inhibition of DNA-PK. To investigate whether DNA-PKcs is a target for wortmannin in vivo, we incubated HL60 cells in the presence of this molecule. After incubation with the drug for 90 min, nuclear extracts were prepared, and Western blotting was performed using the antiwortmannin antibody. Fig. 5A
clearly shows that a major labeled band that comigrates with wortmannin-labeled DNA-PKcs, is present in wortmannin-treated HL60 nuclear extracts. A similar comigrating band is present in wortmannin-treated HeLa nuclear extract. To establish unequivocally that the wortmannin-labeled polypeptide in these studies is, indeed, DNA-PKcs, we treated the DNA-PKcs-negative cell line MO59J and its DNA-PKcs parental control line, MO59K (29)
, with wortmannin. Nuclear extracts were then prepared from these cells and analyzed by electrophoresis followed by immunoblotting with the antiwortmannin antiserum. Notably, as shown in Fig. 5B
, such studies reveal a band that comigrates with purified DNA-PKcs that is present in the DNA-PKcs positive line but absent in the DNA-PKcs null line. These data, therefore, reveal that DNA-PKcs is, indeed, a physiological target for wortmannin.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In addition, we have investigated the mode of wortmannin action on DNA-PK in more detail. Thus, we have shown that, as is the case for PI 3-kinase, wortmannin forms covalent adducts with DNA-PKcs in the region of the molecule harboring its kinase domain and that the formation of such adducts is inhibited competitively by ATP. In light of previous work mapping the site of wortmannin binding to PI 3-kinase and the homology between this kinase and DNA-PKcs, it seems likely that wortmannin targets the lysine at amino acid residue 3751 of the DNA-PKcs polypeptide. Having established that wortmannin targets the ATP-binding site of DNA-PKcs, we then moved on to use it as a probe for the status of the DNA-PKcs active site under various circumstances. Previous studies had revealed that DNA-PKcs catalytic function is stimulated greatly by the simultaneous presence of the Ku heterodimer and DNA ends, raising the possibility that this activation mechanism is mediated via conformational changes in the DNA-PKcs catalytic domain to permit ATP binding. However, we found that wortmannin is able to access DNA-PKcs efficiently in the absence of Ku and/or DNA. Thus, although alternative explanations exist, it seems likely that DNA-PK activation does not reflect opening of the ATP-binding site and, instead, is via activating ATP hydrolytic potential and/or access to the peptide substrate. Finally, we used the fact that wortmannin forms covalent adducts with DNA-PKcs to demonstrate that DNA-PKcs is a major target for wortmannin in intact cells.
Previous analyses of the PI 3-kinase family have revealed that it can be roughly divided into two distinct subgroups on the basis of polypeptide size and through characteristic sequence homologies within the PI 3-kinase catalytic domain (17) . One of these subgroups comprises the PI 3-kinases and PI 4-kinases, most of which appear to be largely membrane associated or cytoplasmic enzymes involved in intracellular signalling or vesicular trafficking. The other subgroup comprises DNA-PKcs and a series of other large (Mr >250,000) proteins that are involved in cell cycle control, DNA damage signaling, and/or DNA repair. A noteworthy feature of our work is that it broadens the inhibitory profiles of wortmannin, LY294002, and their relatives to a key member of the second subgroup. This is important for several reasons. (a) It reveals that these compounds are not as specific to the PI 3-kinases and PI 4-kinases as previously thought, meaning that studies analyzing their in vivo effects should be interpreted with some caution. (b) It raises the prospect that these small molecule inhibitors also target other members of the DNA-PKcs subgroup of the PI 3-kinase family. In line with this prediction, it has been shown recently that the protein kinase function of two other members of this subgroup, ATM and the human cell cycle checkpoint protein ATR, are inhibited by wortmannin (23 , 28) . (c) It raises the exciting prospect that derivatives of wortmannin and LY294002 could serve as the basis for the development of more specific inhibitors of DNA-PKcs and its relatives. Given the involvement of DNA-PK and some of its close relatives in DNA repair processes and because it has already been shown that wortmannin and LY294002 radiosensitize mammalian cells in culture (24, 25, 26, 27) , an attractive potential application for such inhibitory drugs is the enhancement of the efficacy of cancer chemotherapy and radiotherapy.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 This work was funded by the Cancer Research Campaign. 
2 To whom requests for reprints should be addressed, at Wellcome/CRC Institute, Tennis Court Road, Cambridge CB2 1QR, United Kingdom. Phone: 44 01223 334102; Fax: 44 01223 334089; E-mail: spj13{at}mole.bio.cam.ac.uk
3 The abbreviations used are: DNA-PK, DNA-dependent protein kinase; DNA-PKcs, DNA-PK catalytic subunit; IR, ionizing radiation; PI, phosphatidylinositol.
Received 9/ 8/98. Accepted 4/ 2/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W. G. McKenna, S. Patel, and E. J. Bernhard Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity Cancer Res., July 15, 2008; 68(14): 5915 - 5923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Willmore, S. L. Elliott, T. Mainou-Fowler, G. P. Summerfield, G. H. Jackson, F. O'Neill, C. Lowe, A. Carter, R. Harris, A. R. Pettitt, et al. DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3984 - 3992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Kao, Z. Jiang, A. M. Fernandes, A. K. Gupta, and A. Maity Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation J. Biol. Chem., July 20, 2007; 282(29): 21206 - 21212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir Cancer Res., May 1, 2007; 67(9): 4467 - 4473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Geng, X. Zhang, S. Zheng, and R. J. Legerski Artemis Links ATM to G2/M Checkpoint Recovery via Regulation of Cdk1-Cyclin B Mol. Cell. Biol., April 1, 2007; 27(7): 2625 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Al-Alwan, K. Okkenhaug, B. Vanhaesebroeck, J. S. Hayflick, and A. J. Marshall Requirement for Phosphoinositide 3-Kinase p110{delta} Signaling in B Cell Antigen Receptor-Mediated Antigen Presentation J. Immunol., February 15, 2007; 178(4): 2328 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. de la Pena, W. E. Burgan, D. J. Carter, M. G. Hollingshead, M. Satyamitra, K. Camphausen, and P. J. Tofilon Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1504 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, H. D. Thomas, M. A. Batey, I. G. Cowell, C. J. Richardson, R. J. Griffin, A. H. Calvert, D. R. Newell, G. C.M. Smith, and N. J. Curtin Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441. Cancer Res., May 15, 2006; 66(10): 5354 - 5362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sakasai, K. Shinohe, Y. Ichijima, N. Okita, A. Shibata, K. Asahina, and H. Teraoka Differential involvement of phosphatidylinositol 3-kinase-related protein kinases in hyperphosphorylation of replication protein A2 in response to replication-mediated DNA double-strand breaks Genes Cells, March 1, 2006; 11(3): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Frasca, E. Van der Put, A. M. Landin, D. Gong, R. L. Riley, and B. B. Blomberg RNA Stability of the E2A-Encoded Transcription Factor E47 Is Lower in Splenic Activated B Cells from Aged Mice J. Immunol., November 15, 2005; 175(10): 6633 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Parsons Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer Clin. Cancer Res., November 15, 2005; 11(22): 7965 - 7966. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yaneva, H. Li, T. Marple, and P. Hasty Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor Nucleic Acids Res., September 21, 2005; 33(16): 5320 - 5330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Santiago-Walker, A. J. Fikaris, G. D. Kao, E. J. Brown, M. G. Kazanietz, and J. L. Meinkoth Protein Kinase C {delta} Stimulates Apoptosis by Initiating G1 Phase Cell Cycle Progression and S Phase Arrest J. Biol. Chem., September 16, 2005; 280(37): 32107 - 32114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Poh and S. Pervaiz LY294002 and LY303511 Sensitize Tumor Cells to Drug-Induced Apoptosis via Intracellular Hydrogen Peroxide Production Independent of the Phosphoinositide 3-Kinase-Akt Pathway Cancer Res., July 15, 2005; 65(14): 6264 - 6274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Erker, R. Schubert, H. Yakushiji, C. Barlow, D. Larson, J. B. Mitchell, and A. Wynshaw-Boris Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor Hum. Mol. Genet., June 15, 2005; 14(12): 1699 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Deriano, O. Guipaud, H. Merle-Beral, J.-L. Binet, M. Ricoul, G. Potocki-Veronese, V. Favaudon, Z. Maciorowski, C. Muller, B. Salles, et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway Blood, June 15, 2005; 105(12): 4776 - 4783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bladen, D. Udayakumar, Y. Takeda, and W. S. Dynan Identification of the Polypyrimidine Tract Binding Protein-associated Splicing Factor{middle dot}p54(nrb) Complex as a Candidate DNA Double-strand Break Rejoining Factor J. Biol. Chem., February 18, 2005; 280(7): 5205 - 5210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kysela, M. Chovanec, and P. A. Jeggo Phosphorylation of linker histones by DNA-dependent protein kinase is required for DNA ligase IV-dependent ligation in the presence of histone H1 PNAS, February 8, 2005; 102(6): 1877 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hickson, Y. Zhao, C. J. Richardson, S. J. Green, N. M. B. Martin, A. I. Orr, P. M. Reaper, S. P. Jackson, N. J. Curtin, and G. C. M. Smith Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM Cancer Res., December 15, 2004; 64(24): 9152 - 9159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, J. Succi, Z. Feng, S. Prithivirajsingh, M. D. Story, and R. J. Legerski Artemis Is a Phosphorylation Target of ATM and ATR and Is Involved in the G2/M DNA Damage Checkpoint Response Mol. Cell. Biol., October 15, 2004; 24(20): 9207 - 9220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Block, Y. Yu, D. Merkle, J. L. Gifford, Q. Ding, K. Meek, and S. P. Lees-Miller Autophosphorylation-dependent remodeling of the DNA-dependent protein kinase catalytic subunit regulates ligation of DNA ends Nucleic Acids Res., August 16, 2004; 32(14): 4351 - 4357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Solomon, M. C. Cardoso, and E. S. Knudsen Dynamic targeting of the replication machinery to sites of DNA damage J. Cell Biol., August 16, 2004; 166(4): 455 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Willmore, S. de Caux, N. J. Sunter, M. J. Tilby, G. H. Jackson, C. A. Austin, and B. W. Durkacz A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia Blood, June 15, 2004; 103(12): 4659 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tanno, N. Yanagawa, A. Habiro, K. Koizumi, Y. Nakano, M. Osanai, Y. Mizukami, T. Okumura, J. R. Testa, and Y. Kohgo Serine/Threonine Kinase AKT Is Frequently Activated in Human Bile Duct Cancer and Is Associated with Increased Radioresistance Cancer Res., May 15, 2004; 64(10): 3486 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Block, D. Merkle, K. Meek, and S. P. Lees-Miller Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine Nucleic Acids Res., April 1, 2004; 32(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stiff, M. O'Driscoll, N. Rief, K. Iwabuchi, M. Lobrich, and P. A. Jeggo ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation Cancer Res., April 1, 2004; 64(7): 2390 - 2396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kashishian, H. Douangpanya, D. Clark, S. T. Schlachter, C. T. Eary, J. G. Schiro, H. Huang, L. E. Burgess, E. A. Kesicki, and J. Halbrook DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer Mol. Cancer Ther., December 1, 2003; 2(12): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Li, Y. Takeda, S. Wragg, J. Barrett, A. Phillips, and W. S. Dynan Modification of the ionizing radiation response in living cells by an scFv against the DNA-dependent protein kinase Nucleic Acids Res., October 15, 2003; 31(20): 5848 - 5857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Durant and P. Karran Vanillins--a novel family of DNA-PK inhibitors Nucleic Acids Res., October 1, 2003; 31(19): 5501 - 5512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Veuger, N. J. Curtin, C. J. Richardson, G. C. M. Smith, and B. W. Durkacz Radiosensitization and DNA Repair Inhibition by the Combined Use of Novel Inhibitors of DNA-dependent Protein Kinase and Poly(ADP-Ribose) Polymerase-1 Cancer Res., September 15, 2003; 63(18): 6008 - 6015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sak, M. Stuschke, R. Wurm, G. Schroeder, B. Sinn, G. Wolf, and V. Budach Selective Inactivation of DNA-dependent Protein Kinase with Antisense Oligodeoxynucleotides: Consequences for the Rejoining of Radiation-induced DNA Double-Strand Breaks and Radiosensitivity of Human Cancer Cell Lines Cancer Res., November 15, 2002; 62(22): 6621 - 6624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Krystal, G. Sulanke, and J. Litz Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Edwards, L. Geng, J. Tan, H. Onishko, E. Donnelly, and D. E. Hallahan Phosphatidylinositol 3-Kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation Cancer Res., August 15, 2002; 62(16): 4671 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Dash, S. A. Mach, S. Blum, and A. N. Moore Intrahippocampal Wortmannin Infusion Enhances Long-Term Spatial and Contextual Memories Learn. Mem., July 1, 2002; 9(4): 167 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Karmakar, J. Piotrowski, R. M. Brosh Jr., J. A. Sommers, S. P. L. Miller, W.-H. Cheng, C. M. Snowden, D. A. Ramsden, and V. A. Bohr Werner Protein Is a Target of DNA-dependent Protein Kinase in Vivo and in Vitro, and Its Catalytic Activities Are Regulated by Phosphorylation J. Biol. Chem., May 17, 2002; 277(21): 18291 - 18302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blancher, J. W. Moore, N. Robertson, and A. L. Harris Effects of ras and von Hippel-Lindau (VHL) Gene Mutations on Hypoxia-inducible Factor (HIF)-1{alpha}, HIF-2{alpha}, and Vascular Endothelial Growth Factor Expression and Their Regulation by the Phosphatidylinositol 3'-Kinase/Akt Signaling Pathway Cancer Res., October 1, 2001; 61(19): 7349 - 7355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tezuka, H. Watanabe, S. Nakamura, D. Yu, W. Aung, T. Sasaki, H. Shibuya, and M. Miura Antiapoptotic Activity Is Dispensable for Insulin-like Growth Factor I Receptor-mediated Clonogenic Radioresistance after {gamma}-Irradiation Clin. Cancer Res., October 1, 2001; 7(10): 3206 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pospiech, A. K. Rytkonen, and J. E. Syvaoja The role of DNA polymerase activity in human non-homologous end joining Nucleic Acids Res., August 1, 2001; 29(15): 3277 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gupta, V. J. Bakanauskas, G. J. Cerniglia, Y. Cheng, E. J. Bernhard, R. J. Muschel, and W. G. McKenna The Ras Radiation Resistance Pathway Cancer Res., May 1, 2001; 61(10): 4278 - 4282. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Han, S. Harada, D. Weaver, Y. Xue, W. Lane, S. Orstavik, B. Skalhegg, and E. Kieff EBNA-LP Associates with Cellular Proteins Including DNA-PK and HA95 J. Virol., March 1, 2001; 75(5): 2475 - 2481. [Abstract] [Full Text]
|
|
|
|
|
|
D. Kultz and D. Chakravarty Hyperosmolality in the form of elevated NaCl but not urea causes DNA damage in murine kidney cells PNAS, February 13, 2001; 98(4): 1999 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Danilkovitch, S. Donley, A. Skeel, and E. J. Leonard Two Independent Signaling Pathways Mediate the Antiapoptotic Action of Macrophage-Stimulating Protein on Epithelial Cells Mol. Cell. Biol., March 15, 2000; 20(6): 2218 - 2227. [Abstract] [Full Text]
|
|
|
|
|
|
G. C. M. Smith, R. B. Cary, N. D. Lakin, B. C. Hann, S.-H. Teo, D. J. Chen, and S. P. Jackson Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM PNAS, September 28, 1999; 96(20): 11134 - 11139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Frit, R.-Y. Li, D. Arzel, B. Salles, and P. Calsou Ku Entry into DNA Inhibits Inward DNA Transactions in Vitro J. Biol. Chem., November 10, 2000; 275(46): 35684 - 35691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-P. Li, S. Periyasamy, T. J. Jones, and E. R. Sanchez Heat and Chemical Shock Potentiation of Glucocorticoid Receptor Transactivation Requires Heat Shock Factor (HSF) Activity. MODULATION OF HSF BY VANADATE AND WORTMANNIN J. Biol. Chem., August 18, 2000; 275(34): 26058 - 26065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Geddis, N. E. Fox, and K. Kaushansky Phosphatidylinositol 3-Kinase Is Necessary but Not Sufficient for Thrombopoietin-induced Proliferation in Engineered Mpl-bearing Cell Lines as Well as in Primary Megakaryocytic Progenitors J. Biol. Chem., September 7, 2001; 276(37): 34473 - 34479. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
), 0.01 µM (
), 0.1 µM (•), 0.5 µM (
), 1 µM (
), or 5 µM (
